BRAF and colorectal carcinoma: Interestingly, while BRAFV600E mutations occur in about 10% of CRC cases [2] and are an important negative prognostic biomarker for CRC [4–6], the frequency of BRAF mutations among metastatic MSI tumors is much higher (approximately 35%) than among chromosomal instable tumors (<5%) [2].